{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:23:00Z","timestamp":1791901380290,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T00:00:00Z","timestamp":1293580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s10456-010-9197-6","type":"journal-article","created":{"date-parts":[[2010,12,28]],"date-time":"2010-12-28T03:59:44Z","timestamp":1293508784000},"page":"135-141","source":"Crossref","is-referenced-by-count":63,"title":["Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review"],"prefix":"10.1007","volume":"14","author":[{"given":"Maudy","family":"Walraven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella O.","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn P. J.","family":"Lolkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van Hillegersberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile E.","family":"Voest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M. W.","family":"Verheul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,29]]},"reference":[{"issue":"1","key":"9197_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1):4\u20136","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"9197_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581\u2013611","journal-title":"Endocr Rev"},{"issue":"7","key":"9197_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2174\/1566524033479465","volume":"3","author":"J Folkman","year":"2003","unstructured":"Folkman J (2003) Fundamental concepts of the angiogenic process. Curr Mol Med 3(7):643\u2013651","journal-title":"Curr Mol Med"},{"issue":"1","key":"9197_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2007.01.038","volume":"105","author":"ES Han","year":"2007","unstructured":"Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105(1):3\u20136","journal-title":"Gynecol Oncol"},{"issue":"23","key":"9197_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350(23):2335\u20132342","journal-title":"New Engl J Med"},{"issue":"1","key":"9197_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25\u201335","journal-title":"J Clin Oncol"},{"key":"9197_CR7","doi-asserted-by":"crossref","unstructured":"De Mulder PH, Roigas J, Gillessen S, Srinivas S, Pisa P, Vogelzang N, Fountzilas G, Peschel C, Baum C, Escudier B (2006) A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 24(1), 18S(June 20 Suppl):abstr 4529","DOI":"10.1200\/jco.2006.24.18_suppl.4529"},{"key":"9197_CR8","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly EM, Niedzwiecki D, Hollis DR, Bekaii-Saab TS, Pluard T, Duffy A, Overcash F, Ivy SP, Goldberg RM (2008) A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol 26 (May 20 Suppl):abstr 4515","DOI":"10.1200\/jco.2008.26.15_suppl.4515"},{"issue":"19","key":"9197_CR9","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","volume":"27","author":"RG Maki","year":"2009","unstructured":"Maki RG, D\u2019Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachere NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27(19):3133\u20133140","journal-title":"J Clin Oncol"},{"key":"9197_CR10","doi-asserted-by":"crossref","unstructured":"Min CJ, Liebes LF, Escalon J, Hamilton A, Yee H, Buckley MT, Wright JJ, Osman I, Polsky D, Pavlick AC (2008) Phase II trial of sorafenib (S [BAY 43-9006]) in metastatic melanoma (MM) including detection of BRAF with mutant specific-PCR (MS-PCR) and altered proliferation pathways-final outcome analysis. J Clin Oncol 26 (May 20 Suppl):abstr 9072","DOI":"10.1200\/jco.2008.26.15_suppl.9072"},{"key":"9197_CR11","doi-asserted-by":"crossref","unstructured":"Wiebe L, Kasza KE, Maki RG, D\u2019Adamo DR, Chow WA, Wade JL, Agamah E, Stadler WM, Vokes EE, Kindler HL (2008) Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26(May 20 Suppl): abstr 10502","DOI":"10.1200\/jco.2008.26.15_suppl.10502"},{"key":"9197_CR12","doi-asserted-by":"crossref","unstructured":"El-Khoueiry AB, Rankin C, Lenz HJ, Philip P, Rivkin SE, Blanke CD (2007) SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol 25(1),18S(June 20 Suppl):abstr 4639","DOI":"10.1200\/jco.2007.25.18_suppl.4639"},{"key":"9197_CR13","doi-asserted-by":"crossref","unstructured":"Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, Fukino K, Tanigawa T, Nakagawa K (2009) Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Investig New Drugs","DOI":"10.1007\/s10637-009-9321-x"},{"issue":"2","key":"9197_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejso.2007.09.009","volume":"35","author":"FC Eng","year":"2009","unstructured":"Eng FC, Easson AM, Szentgyorgyi E, Knox JJ (2009) Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol 35(2):219\u2013221","journal-title":"Eur J Surg Oncol"},{"issue":"14","key":"9197_CR15","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","volume":"26","author":"NA Peters","year":"2008","unstructured":"Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ (2008) Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 26(14):2405\u20132406","journal-title":"J Clin Oncol"},{"issue":"39","key":"9197_CR16","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.3748\/wjg.14.6096","volume":"14","author":"H Hur","year":"2008","unstructured":"Hur H, Park AR, Jee SB, Jung SE, Kim W, Jeon HM (2008) Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. World J Gastroenterol 14(39):6096\u20136099","journal-title":"World J Gastroenterol"},{"issue":"Suppl 2","key":"9197_CR17","first-page":"27","volume":"15","author":"W Ruka","year":"2009","unstructured":"Ruka W, Rutkowski P, Nowecki Z, Dziewirski W (2009) Emergency surgery due to complications during molecular targeted therapy in advanced gastrointestinal stromal tumors (GIST). Ann Surg Oncol 15(Suppl 2):27(abstr 82)","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"9197_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","volume":"24","author":"CP Raut","year":"2006","unstructured":"Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24(15):2325\u20132331","journal-title":"J Clin Oncol"},{"issue":"1","key":"9197_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10637-008-9146-z","volume":"27","author":"TW Flaig","year":"2009","unstructured":"Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Investig New Drugs 27(1):83\u201387","journal-title":"Investig New Drugs"},{"issue":"28\u201329","key":"9197_CR20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0029-1225311","volume":"134","author":"T Frieling","year":"2009","unstructured":"Frieling T, Heise J, Wassilew SW (2009) Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. Deutsche medizinische Wochenschrift (1946) 134(28\u201329):e1\u2013e2, 1464\u20131466","journal-title":"Deutsche medizinische Wochenschrift"},{"issue":"11","key":"9197_CR21","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","volume":"20","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 20(11):1842\u20131847","journal-title":"Ann Oncol"},{"issue":"6","key":"9197_CR22","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1245\/s10434-006-9337-9","volume":"14","author":"MW Saif","year":"2007","unstructured":"Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14(6):1860\u20131869","journal-title":"Ann Surg Oncol"},{"key":"9197_CR23","doi-asserted-by":"crossref","unstructured":"Sugrue M, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Steis R, Dong W, Sarkar S, Grothey A (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 24(1), 18S (June 20 Suppl):abstr 3535","DOI":"10.1200\/jco.2006.24.18_suppl.3535"},{"issue":"3","key":"9197_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/annonc\/mdm508","volume":"19","author":"BD Badgwell","year":"2008","unstructured":"Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19(3):577\u2013582","journal-title":"Ann Oncol"},{"issue":"16","key":"9197_CR25","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697\u20133705","journal-title":"J Clin Oncol"},{"key":"9197_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11523-008-0075-8","volume":"3","author":"AA Parikh","year":"2008","unstructured":"Parikh AA, Ellis LM (2008) Targeted therapies and surgical issues in gastrointestinal cancers. Targ Oncol 3:119\u2013125","journal-title":"Targ Oncol"},{"issue":"4","key":"9197_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10637-008-9125-4","volume":"26","author":"J Tol","year":"2008","unstructured":"Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ (2008) Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Investig New Drugs 26(4):393\u2013397","journal-title":"Investig New Drugs"},{"issue":"3\u20134","key":"9197_CR28","first-page":"301","volume":"29","author":"M Yoshida","year":"2003","unstructured":"Yoshida M, Wakabayashi G, Ishikawa H, Kameyama K, Shimazu M, Tanabe M, Kawachi S, Kumai K, Kubota T, Otani Y, Saikawa Y, Sano K, Kitajima M (2003) A possible defensive mechanism in the basal region of gastric mucosa and the healing of erosions. Clin Hemorheol Microcirc 29(3\u20134):301\u2013312","journal-title":"Clin Hemorheol Microcirc"},{"issue":"Suppl 1","key":"9197_CR29","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1007\/s10620-005-2803-6","volume":"50","author":"AS Tarnawski","year":"2005","unstructured":"Tarnawski AS (2005) Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 50(Suppl 1):S24\u2013S33","journal-title":"Dig Dis Sci"},{"issue":"2","key":"9197_CR30","first-page":"259","volume":"56","author":"B Malara","year":"2005","unstructured":"Malara B, Josko J, Tyrpien M, Malara P, Steplewska K (2005) Dynamics of changes in vascular endothelial growth factor (VEGF) expression and angiogenesis in stress-induced gastric ulceration in rats. J Physiol Pharmacol 56(2):259\u2013271","journal-title":"J Physiol Pharmacol"},{"issue":"1","key":"9197_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/jnci\/djk011","volume":"99","author":"O Mir","year":"2007","unstructured":"Mir O, Mouthon L, Alexandre J, Mallion JM, Deray G, Guillevin L, Goldwasser F (2007) Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 99(1):85\u201386","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9197_CR32","first-page":"H560","volume":"290","author":"T Kamba","year":"2006","unstructured":"Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O\u2019Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol 290(2):H560\u2013H576","journal-title":"Am J Physiol"},{"issue":"33","key":"9197_CR33","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","volume":"25","author":"SA Cannistra","year":"2007","unstructured":"Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180\u20135186","journal-title":"J Clin Oncol"},{"issue":"1","key":"9197_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ygyno.2007.06.004","volume":"107","author":"F Simpkins","year":"2007","unstructured":"Simpkins F, Belinson JL, Rose PG (2007) Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107(1):118\u2013123","journal-title":"Gynecol Oncol"},{"issue":"18 Pt 1","key":"9197_CR35","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1158\/1078-0432.CCR-07-0847","volume":"13","author":"HM Verheul","year":"2007","unstructured":"Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE (2007) Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 13(18 Pt 1):5341\u20135347","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9197_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc2152","volume":"7","author":"HM Verheul","year":"2007","unstructured":"Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev 7(6):475\u2013485","journal-title":"Nat Rev"},{"issue":"1","key":"9197_CR37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-0037-1615158","volume":"80","author":"U Wartiovaara","year":"1998","unstructured":"Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A (1998) Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 80(1):171\u2013175","journal-title":"Thromb Haemost"},{"issue":"1\u20133","key":"9197_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0014-5793(02)02232-9","volume":"512","author":"F Selheim","year":"2002","unstructured":"Selheim F, Holmsen H, Vassbotn FS (2002) Identification of functional VEGF receptors on human platelets. FEBS Lett 512(1\u20133):107\u2013110","journal-title":"FEBS Lett"},{"issue":"2","key":"9197_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1073\/pnas.94.2.663","volume":"94","author":"R Mohle","year":"1997","unstructured":"Mohle R, Green D, Moore MA, Nachman RL, Rafii S (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94(2):663\u2013668","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12 Pt 1","key":"9197_CR40","first-page":"2187","volume":"3","author":"HM Verheul","year":"1997","unstructured":"Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3(12 Pt 1):2187\u20132190","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9197_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0024-3205(98)00296-3","volume":"63","author":"Y Okuda","year":"1998","unstructured":"Okuda Y, Tsurumaru K, Suzuki S, Miyauchi T, Asano M, Hong Y, Sone H, Fujita R, Mizutani M, Kawakami Y, Nakajima T, Soma M, Matsuo K, Suzuki H, Yamashita K (1998) Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci 63(6):477\u2013484","journal-title":"Life Sci"},{"issue":"6","key":"9197_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10(6):559\u2013568","journal-title":"Lancet Oncol"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-010-9197-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10456-010-9197-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-010-9197-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-010-9197-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T01:13:23Z","timestamp":1592183603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10456-010-9197-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,29]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["9197"],"URL":"https:\/\/doi.org\/10.1007\/s10456-010-9197-6","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,29]]}}}